Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Overlevenden van gemetastaseerd melanoom hebben moeite hun leven te hervatten
aug 2022 | Dermato-oncologie